<code id='67181EE022'></code><style id='67181EE022'></style>
    • <acronym id='67181EE022'></acronym>
      <center id='67181EE022'><center id='67181EE022'><tfoot id='67181EE022'></tfoot></center><abbr id='67181EE022'><dir id='67181EE022'><tfoot id='67181EE022'></tfoot><noframes id='67181EE022'>

    • <optgroup id='67181EE022'><strike id='67181EE022'><sup id='67181EE022'></sup></strike><code id='67181EE022'></code></optgroup>
        1. <b id='67181EE022'><label id='67181EE022'><select id='67181EE022'><dt id='67181EE022'><span id='67181EE022'></span></dt></select></label></b><u id='67181EE022'></u>
          <i id='67181EE022'><strike id='67181EE022'><tt id='67181EE022'><pre id='67181EE022'></pre></tt></strike></i>

          explore

          explore

          author:focus    Page View:9
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Canadians with cystic fibrosis outlive Americans by a decade
          Canadians with cystic fibrosis outlive Americans by a decade

          Michel,acysticfibrosispatientfromMascouche,Québec,Canada,seenhereatoneoftheclinicsthatcontributeddat

          read more
          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more

          In utero gene editing: an explainer

          AnnaYeo/STATRecentlyapprovedgenetherapiesofferpatientsone-time,potentiallycurativetreatmentsforgenet